Guggenheim Maintains Buy on Twist Bioscience, Raises Price Target to $55

Guggenheim analyst Subbu Nambi has maintained a Buy rating on Twist Bioscience (NASDAQ: TWST) and raised the price target from $50 to $55. This adjustment reflects a positive outlook for the company's performance in the market.